Optimization of collimator angles in dual-arc volumetric modulated arc therapy planning for whole-brain radiotherapy with hippocampus and inner ear sparing

Wuji Sun1,4, Kunzhi Chen1,4, Yu Li1, Wenming Xia1, Lihua Dong1,2,3, Yinghua Shi1, Chao Ge1, Xu Yang1, Libo Wang1 & Huidong Wang1

To optimize the collimator angles in dual-arc volumetric modulated arc therapy (VMAT) plans for whole-brain radiotherapy with hippocampus and inner ear sparing (HIS-WBRT). Two sets of dual-arc VMAT plans were generated for 13 small-cell lung cancer patients: (1) The collimator angles of arcs 1 and 2 (θ1/θ2) were 350°/10°, 350°/30°, 350°/45°, 350°/60°, and 350°/80°, i.e., the intersection angle of θ1 and θ2 (Δθ) increased. (2) θ1/θ2 were 280°/10°, 300°/30°, 315°/45°, 330°/60°, and 350°/80°, i.e., Δθ = 90°. The conformity index (CI), homogeneity index (HI), monitor units (MUs), and dosimetric parameters of organs-at-risk were analyzed. Quality assurance for Δθ = 90° plans was performed. With Δθ increasing towards 90°, a significant improvement was observed for most parameters. In 350°/80° plans compared with 350°/10° ones, CI and HI were improved by 1.1% and 25.2%, respectively; MUs were reduced by 16.2%; minimum, maximum, and mean doses (D100%, Dmax, and Dmean, respectively) to the hippocampus were reduced by 5.5%, 6.3%, and 5.4%, respectively; Dmean to the inner ear and eye were reduced by 0.7% and 5.1%, respectively. With Δθ kept at 90°, the plan quality was not significantly affected by θ1/θ2 combinations. The gamma-index passing rates in 280°/10° and 350°/80° plans were relatively lower compared with the other Δθ = 90° plans. Δθ showed a significant effect on dual-arc VMAT plans for HIS-WBRT. With Δθ approaching 90°, the plan quality exhibited a nearly continuous improvement, whereas with Δθ = 90°, the effect of θ1/θ2 combination was insignificant.

Whole-brain radiotherapy (WBRT) has been used for the treatment of brain metastases or the prophylactic cranial irradiation of patients with small-cell lung cancer in the past decades1–3. However, the neurocognitive deficits caused by the radiation, including memory loss and cognitive impairment, have always been a concern4,5. The damage to the neural stem cell compartment in the hippocampus is generally believed to be the main cause6,7. The Radiation Therapy Oncology Group (RTOG) 0933 trial has demonstrated promising results in reducing the adverse neurocognitive effect of WBRT with hippocampus and inner ear sparing (HIS-WBRT) compared with conventional WBRT7–9. In the RTOG 0933 protocol, the target coverage and the dose to the organs-at-risk (OARs) were strictly constrained to achieve a reasonable dose distribution, and intensity-modulated radiation therapy (IMRT) modalities are required9. Volumetric modulated arc therapy (VMAT) is usually preferred because of its higher delivery efficiency than fixed-gantry IMRT10,11.

Current VMAT implementation does not allow collimator rotation during delivery, and the collimator angle in each arc is required to be determined before plan optimization12. Numerous studies have investigated the

1Department of Radiation Oncology and Therapy, The First Hospital of Jilin University, Changchun 130021, China. 2Jilin Provincial Key Laboratory of Radiation Oncology and Therapy, Department of Radiation Oncology and Therapy, The First Hospital of Jilin University, Changchun 130021, China. 3NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun 130021, China. 4These authors contributed equally: Wuji Sun and Kunzhi Chen. *email: wang_hd2010@jlu.edu.cn
In this study, the collimator angle of dual-arc VMAT for HIS-WBRT was optimized in two steps. First, the intersection angle between arcs should be investigated to optimize the collimator angle. In particular, for dual-arc VMAT, the intersection angle between two collimator settings may have a significant effect on the plan optimization. By rotating the collimator between arcs, a better dose distribution could be achieved with the multi-leaf collimator (MLC) moving directions orthogonal to each other.

In this study, the collimator angle of dual-arc VMAT for HIS-WBRT was optimized in two steps. First, the plan quality with different intersection angles between arcs was evaluated to find the most adequate choice. Second, with the optimal intersection angle, the specific collimator setting of each arc was investigated on the basis of plan quality evaluation and quality assurance (QA).

### Materials and methods

#### Patient selection and contouring

A total of 13 patients with small-cell lung cancer, who had been previously treated in 2018–2020 in the First Hospital of Jilin University, were retrospectively included. The patients were immobilized in supine position by using a thermoplastic mask (Klarity Medical & Equipment Co. Ltd., Guangzhou, China). Computed tomography (CT) images of the entire head region were acquired using Philips Brilliance Big Bore CT scanner (Philips Healthcare, Cleveland, OH) with 3 mm slice thickness. The T1-weighted contrast-enhanced magnetic resonance imaging sequences, obtained with 1 mm slice thickness, were fused to the plan CT in the Eclipse version 13.5 (Varian Medical Systems, Palo Alto, CA) treatment planning system (TPS).

Anatomical contouring was carried out in accordance with the RTOG 0933 protocol, including the whole brain, hippocampi, inner ears, lenses, optical nerves, and eyes. The planning target volume (PTV) for HIS-WBRT was defined as the whole brain with a 5 mm margin expansion excluding the hippocampus-sparing region. The volumes (mean ± standard deviation (minimum and maximum)) of the hippocampus-sparing region was obtained by adding a 5 mm margin to the hippocampi, for the dose gradient between the hippocampus and PTV. The volumes (mean ± standard deviation (minimum and maximum)) of PTV, hippocampus, and inner ear were 1366.9 ± 114.3 (1099.3 and 1572.5), 3.7 ± 1.1 (1.0 and 5.2), and 1.3 ± 0.6 (0.2 and 2.4) cm³, respectively.

#### Treatment planning

VMAT plans were optimized on Eclipse version 13.5 for 6 MV X-ray beams of a Varian TrueBeam linear accelerator equipped with a Millennium MLC-120 MLC (Varian Medical Systems, Palo Alto, CA). The maximum dose rate was 600 MUs/min. The dose distributions were calculated using the anisotropic analytic algorithm with a grid of 2.5 mm. The jaw tracking was enabled, and the maximum field size (X × Y) was 15 cm × 40 cm to adequately cover the whole brain.

For all patients, a dose of 30 Gy was prescribed in 10 fractions, and all plans complied with the dose criteria of the RTOG 0933 protocol and additional constraints used in this study, as shown in Table 1. Dual-arc VMAT plans for HIS-WBRT were generated for each patient with two coplanar whole arcs. The settings of two collimator angles are denoted by $\theta_1/\theta_2$, i.e., the angles of the first and second arcs. The intersection angle between these two angles, denoted by $\Delta \theta$, ranged from 0° to 90°. Two sets of plans with different $\theta_1/\theta_2$ were generated as follows:

1. $\theta_1/\theta_2$ were set as 350°/10°, 350°/30°, 350°/45°, 350°/60°, and 350°/80°, i.e., $\Delta \theta$ increased from 20° to 90°; and
2. $\theta_1/\theta_2$ were set as 280°/10°, 300°/30°, 315°/45°, 330°/60°, and 350°/80°, i.e., $\Delta \theta$ was fixed at 90°.

For each patient, all plans were optimized with identical dosimetric constraints and normalized to 92% of the PTV receiving 30 Gy, while there were certain adjustments in the optimization methods for different patients to assure that all plans complied with the dose criteria.
Dose Image Prediction version 13.6.23 algorithm was used to calculate the predicted dose images.

The Δθ was defined as26,27

$$\Delta \theta = \theta_2 - \theta_1$$

where θ1 and θ2 indicate the collimator angles of arc 1 and arc 2, respectively. *Statistically significant (p < 0.05).

| Parameter          | 350°/10° | 350°/30° | 350°/45° | 350°/60° | 350°/80° | p-value |
|--------------------|----------|----------|----------|----------|----------|---------|
| PTV                | CI       | 0.848 ± 0.009 | 0.853 ± 0.007 | 0.856 ± 0.007 | 0.858 ± 0.004 | 0.857 ± 0.008 | 0.002* |
| HI                 | 0.259 ± 0.023 | 0.212 ± 0.016 | 0.202 ± 0.016 | 0.199 ± 0.012 | 0.194 ± 0.019 | < 0.001* |
| Hippocampus        | Dmax (cGy) | 929.7 ± 40.1 | 891.1 ± 32.8 | 884.2 ± 25.1 | 880.5 ± 31.7 | 878.8 ± 29.2 | < 0.001* |
|                    | Dmean (cGy) | 1507.2 ± 105.6 | 1433.0 ± 77.7 | 1422.0 ± 65.7 | 1434.2 ± 76.7 | 1412.7 ± 79.3 | < 0.001* |
|                    | 1/200% (cGy) | 1053.8 ± 27.6 | 1056.5 ± 31.0 | 1038.8 ± 29.7 | 1049.6 ± 29.7 | 1043.3 ± 30.3 | < 0.001* |
| Inner ear          | Dmax (cGy) | 1437.6 ± 40.3 | 1433.0 ± 20.1 | 1429.5 ± 30.0 | 1427.4 ± 29.8 | 1427.3 ± 29.1 | 0.008* |
| Eye                | Dmax (cGy) | 970.9 ± 37.5 | 943.2 ± 18.3 | 934.0 ± 17.6 | 930.5 ± 11.6 | 921.0 ± 20.9 | < 0.001* |
| Monitor Unit       | MU       | 1073.6 ± 118.8 | 929.5 ± 44.6 | 908.7 ± 33.9 | 900.6 ± 28.5 | 899.5 ± 28.2 | < 0.001* |

Table 2. Dosimetric parameters and MUs of VMAT plans with intersection angle of two collimators (Δθ) changing from 20° to 90°, along with their Friedman test results. *Statistically significant (p < 0.05).

Treatment plan evaluation. Several parameters, including the conformity index (CI), homogeneity index (HI), MUs, and dose-volume histogram (DVH) parameters of OARs, were selected for the plan evaluation with respect to the collimator setting.

The CI and HI were defined as26,27

$$CI = \frac{TV_{PIV}^2}{TV \times PIV}$$

and

$$HI = \frac{D_{2\%} - D_{98\%}}{D_{50\%}}$$

where TV is the target volume, PIV is the prescription isodose volume, TV_{PIV} is the target volume within the prescription isodose volume, and D_{2\%} represents the dose delivered to 2% of the target volume. CI closer to 1 indicates better dose conformity. HI closer to 0 indicates better dose homogeneity.

The evaluated dosimetric parameters of OAR included the minimum, maximum, and mean doses (D_{100\%}, D_{max}, and D_{mean}, respectively) of the hippocampus; the D_{mean} of the inner ear and eye; and the D_{max} of the optical nerve and lens.

Quality assurance. QA was performed for Δθ = 90° plans by using local gamma-index analysis with 3%/3, 3%/2, and 2%/2 mm criteria28, using an a-Si 1200 Electronic Portal Imaging Device with an active area of 40 cm x 40 cm and a pixel number of 1190 x 1190. Dose images were acquired for each arc with a source-to-detector distance of 100 cm and later retrieved to the Portal Dosimetry module of the Eclipse TPS. The Portal Dose Image Prediction version 13.6.23 algorithm was used to calculate the predicted dose images.

Statistical analysis. Friedman test was first carried out for the above parameters within each set of plans, i.e., with different Δθ and same Δθ (=90°), to investigate if Δθ and the specific angle of each arc could affect the plan quality of dual-arc VMAT. Wilcoxon signed-rank test was performed for multiple comparisons between the Δθ = 90° and Δθ < 90° plans. The comparisons were conducted in two groups, that is, (A) between plans with same θ1 but different θ2 and (B) between those with same θ1 but different θ2. The obtained p-values were evaluated with Bonferroni correction.

The above two tests were also used for the gamma-index passing rate evaluation in the plan QA for Δθ = 90° plans. All statistical analyses were performed using IBM SPSS Statistics version 26.0 software (IBM Corporation, Armonk, NY). p < 0.05 was defined as statistically significant.

Ethics approval and consent to participate. All experimental protocols were approved by the Ethics Committee of the First Hospital of Jilin University. The Ethics Committee of the First Hospital of Jilin University waived the need for informed consent. All research was performed in accordance with relevant guidelines and regulations.

Results Table 2 shows the evaluated parameters and their corresponding Friedman test results for the VMAT plans with increasing Δθ. Figure 1 presents the predicted dose distribution of each arc in these plans for a typical patient. The results for plans with the same Δθ (= 90°) are shown in Table 3. Supplementary Fig. S1 presents the calculated dose distribution in one 350°/80° plan for a typical patient and the corresponding DVH compared with that in Δθ < 90° plans.
Figure 1. Predicted dose distribution for each arc of dual-arc VMAT plans in coronal view with collimator settings of (a) 350°/10°, (b) 350°/30°, (c) 350°/45°, (d) 350°/60°, and (e) 350°/80° for a typical patient.

Table 3. Dosimetric parameters and MUs of Δθ = 90° plans, along with their Friedman test results. *Statistically significant (p < 0.001).

| Parameter       | Result for VMAT with collimator angles θ₁/θ₂ | p-value |
|-----------------|---------------------------------------------|---------|
|                  | 280°/10° | 300°/30° | 315°/45° | 330°/60° | 350°/80° |
| PTV CI 0.859 ± 006 | 0.859 ± 008 | 0.858 ± 007 | 0.855 ± 007 | 0.857 ± 008 | 0.501 |
| HI 0.189 ± 013   | 0.193 ± 013 | 0.189 ± 013 | 0.194 ± 011 | 0.194 ± 019 | 0.289 |
| Hippocampus Dₚ₃₀₈₆ (cGy) 879.4 ± 34.5 | 873.5 ± 27.1 | 872.2 ± 28.2 | 869.8 ± 31.3 | 878.8 ± 29.2 | 0.112 |
| Dₚ₃₅₈₀ (cGy) 1415.1 ± 71.1 | 1432.9 ± 69.6 | 1411.6 ± 81.8 | 1415.8 ± 65.5 | 1412.7 ± 79.3 | 0.074 |
| Dₚ₃₅₄₅ (cGy) 1041.7 ± 29.8 | 1045.4 ± 27.5 | 1039.6 ± 31.0 | 1041.6 ± 30.8 | 1043.3 ± 30.3 | 0.412 |
| Inner ear Dₚ₃₈₆ (cGy) 1411.0 ± 56.0 | 1412.6 ± 31.1 | 1407.8 ± 38.1 | 1403.5 ± 49.4 | 1427.3 ± 29.1 | 0.106 |
| Lens Dₚ₃₆₉ (cGy) 669.3 ± 26.1 | 684.6 ± 20.4 | 683.9 ± 24.5 | 698.5 ± 27.8 | 702.4 ± 38.1 | 0.001* |
| Optical nerve Dₚ₃₈₆ (cGy) 3106.7 ± 87.2 | 3180.2 ± 55.6 | 3180.7 ± 96.1 | 3171.5 ± 63.8 | 3087.3 ± 127.0 | 0.001* |
| Eye Dₚ₃₈₆ (cGy) 919.4 ± 22.8 | 922.8 ± 13.9 | 918.2 ± 21.0 | 925.0 ± 9.4 | 921.0 ± 20.9 | 0.421 |
| Monitor unit MU 905.2 ± 37.5 | 878.4 ± 44.4 | 878.5 ± 36.7 | 881.3 ± 36.7 | 899.5 ± 28.2 | 0.003* |

Plan quality with increasing Δθ. As shown in Table 2, Δθ showed a significant effect on the CI, HI, MUs, and dosimetric parameters of the hippocampus (Dₚ₃₅₈₀, Dₚ₃₆₉, and Dₚ₃₆₉), inner ear (Dₚ₃₆₉), and eye (Dₚ₃₆₉), whereas no significance was found in the Dₚ₃₆₉ of lens and optical nerve.

Among the five collimator settings, the 350°/80° (Δθ = 90°) plans exhibited the best HI, MUs, and dosimetric parameters of the hippocampus, inner ear, and eye and the second-best CI. In the 350°/80° plans compared with the 350°/10° ones, the CI and HI were improved by 1.1% (p = 0.007) and 25.2% (p < 0.001), respectively; MUs were reduced by 16.2% (p < 0.001); the Dₚ₃₅₈₀, Dₚ₃₆₉, and Dₚ₃₆₉ to the hippocampus were reduced by 5.5% (p < 0.001), 6.3% (p < 0.001), and 5.4% (p < 0.001), respectively; the Dₚ₃₆₉ to the inner ear was reduced by 0.7% (p = 0.039); and the Dₚ₃₆₉ to the eye was reduced by 5.1% (p < 0.001).

For further investigation of the relation between the plan quality and Δθ, the parameter values in the Δθ = 90° plans minus those in the Δθ < 90° plans are shown in Fig. 2 in two groups: group A, plans with the same θ₁; and group B, plans with the same θ₂ indicated by the solid lines; and group B, plans with the same θ₂ indicated by the dashed lines. The difference in the plan Δθ was denoted by Δθ = 90° − Δθ (< 90°).

With decreasing Δθ, i.e., Δθ increasing towards 90°, improvements were clearly demonstrated for the CI, HI, MUs, and dosimetric parameters of the hippocampus and eye. A high degree of similarity was observed between groups A and B. One-tailed Wilcoxon signed-rank tests were performed for the comparisons within groups A and B, and the results are shown in Supplementary Tables S1 and S2, respectively. Compared with the Δθ < 90° plans, the Δθ = 90° plans generally showed significantly better or similar results depending on Δθ.

Plan quality with same Δθ (90°) and different θ₁/θ₂. As shown in Table 3, θ₁/θ₂ only showed a significant correlation with the MUs and maximum doses to the lens and optical nerve. The 300°/30°, 315°/45°, and 330°/60° plans required higher MUs but reduced Dₚ₃₆₉ to the optical nerve compared with the 280°/10° and 350°/80° plans. As to the Dₚ₃₆₉ of lens, the 280°/10°, 300°/30°, and 315°/45° plans exhibited better results than the 330°/60° and 350°/80° plans. In general, the difference in plan quality was relatively trivial.

Quality assurance for Δθ = 90° plans. The QA results for the Δθ = 90° plans are displayed in Table 4. The passing rate was statistically affected by the collimator setting, and for all gamma criteria, the 280°/10° and 350°/80° plans had significantly lower passing rates than the 300°/30°, 315°/45°, and 330°/60° plans (p < 0.005
for Wilcoxon signed-rank tests). The passing rates of each arc in the 280°/10° and 350°/80° plans are shown in Table 5. The results for 280° and 80° were generally similar and lower than those for 350° and 10°.

**Discussion**

Considering the positive results demonstrated in the RTOG 0933 trail, HIS-WBRT has gradually become a common practice for the treatment of brain metastases and prophylactic cranial irradiation. The plan quality is especially important, and choosing the collimator angle is a vital part of the plan optimization to achieve an ideal dose distribution due to the complexity of HIS-WBRT. In the present study, the collimator

---

Table 4. Passing rates of Δθ = 90° plans using 3%/3, 3%/2, and 2%/2 mm gamma criteria, along with their Friedman test results. *Statistically significant (p < 0.05).

| Gamma criteria | Passing rate for VMAT with collimator angles θ_i/θ_j (%) | p-value |
|----------------|--------------------------------------------------------|---------|
|                | 280°/10° | 300°/30° | 315°/45° | 330°/60° | 350°/80° |       |
| 3%/3 mm        | 97.6 ± 0.6 | 98.3 ± 0.6 | 98.4 ± 0.5 | 98.5 ± 0.5 | 97.6 ± 0.6 | < 0.001* |
| 3%/2 mm        | 95.4 ± 1.0 | 96.9 ± 1.0 | 97.1 ± 0.8 | 97.2 ± 0.8 | 95.5 ± 1.1 | < 0.001* |
| 2%/2 mm        | 90.4 ± 2.2 | 92.7 ± 2.1 | 92.9 ± 1.8 | 93.1 ± 1.9 | 90.4 ± 2.2 | < 0.001* |

---

Figure 2. Variation of parameter differences between Δθ < 90° plans and Δθ = 90° plans with respect to δθ (= 90° − Δθ). Group A shows the differences between plans with the same arc 1 collimator, indicated by the filled symbols and solid lines. Group B shows the differences between plans with the same arc 2 collimator, indicated by the open symbols with dashed lines.
angle had a significant effect on the dose distribution quality and MUs, in agreement with the previous studies. Zhang et al.32 developed a collimator trajectory selection method for VMAT, and an enhanced dose distribution could be achieved by aligning the collimator with the target shape. Several studies showed that the VMAT optimization involving sectional optimization of collimator angle could provide delivery efficiency and dosimetric improvements.33,34 Recent studies on the dynamic collimator rotation approach have shown positive results on improving the plan quality24,35–37.

Table 2 shows that among the five sets of plans with different $\Delta \theta$, the 350°/80° ($\Delta \theta = 90^\circ$) plans had the best overall dosimetric performance and MUs. Figure 2 demonstrates the differences between the $\Delta \theta = 90^\circ$ and $\Delta \theta < 90^\circ$ plans with respect to $\theta$. A visible similarity was present between groups A and B in the improvement of CI, HI, MUs, and doses to the hippocampus and eye with decreasing $\Delta \theta$, indicating that with $\Delta \theta$ increasing towards 90°, the plan quality could be gradually improved.

The five sets of $\Delta \theta = 90^\circ$ plans were compared to investigate the possible effect from the $\theta_1/\theta_2$ combination with the same $\Delta \theta$, and the results are shown in Table 3. Thus, when the intersection $\Delta \theta$ was the same, most parameters showed no significant correlation with $\theta_1/\theta_2$ combinations, except the MUs and maximum doses to lens and optical nerve. Considering the behavior of all parameters, the effect of $\Delta \theta$ was much greater than that of the specific angle of each arc.

The collimator angle should allow the MLC aperture to encompass the PTV while avoiding the sparing region. For the near-spherical target volume in HIS-WBRT, with the avoidance of two hippocampi, which exist bilaterally in the middle of the brain, the plan complexity could be considerably increased compared with conventional WBRT. Many studies proposed that high plan complexity could affect the accuracy of dose calculation and beam delivery.38–40. The predicted dose distribution shown in Fig. 1 indicated that regardless of the collimator setting, the plan optimization tended to form mutually orthogonal dose distributions in two arcs, and the integrated dose distribution could then conform with the complex-shape target volume of HIS-WBRT. With the $\Delta \theta = 90^\circ$ plans, i.e., the MLC orientations of two arcs perpendicular to each other, the motion complexity of MLC could be potentially reduced compared with the $\Delta \theta < 90^\circ$ plans, which could be part of the reason for the improved dose distribution quality of $\Delta \theta = 90^\circ$ plans.

Table 5. Passing rates of each arc in 280°/10° and 350°/80° plans using 3%/3, 3%/2, and 2%/2 mm gamma criteria.

| Gamma criteria | Arc 1 (280°) | Arc 2 (10°) | Arc 1 (350°) | Arc 2 (80°) |
|----------------|-------------|-------------|-------------|-------------|
| 3%/3 mm        | 98.7 ± 0.6  | 99.1 ± 0.3  | 99.3 ± 0.3  | 97.8 ± 1.4  |
| 3%/2 mm        | 95.6 ± 2.2  | 97.6 ± 0.7  | 98.0 ± 0.6  | 95.0 ± 2.6  |
| 2%/2 mm        | 92.2 ± 2.8  | 96.1 ± 1.1  | 96.7 ± 1.0  | 91.6 ± 3.1  |

Previous studies on the effect of collimator angle on VMAT plan quality proposed various optimal settings depending on the tumor site and shape12,17,41. For vertebral metastases, Mancosu et al. suggested a collimator angle of around 90° to align the MLC leaf motion with the spinal cord41. For prostate cancer, Li et al. suggested an angle of 45° for the optimal dose distribution plan complexity42. For nasopharynx cancer, Otto found that 45° was preferable in most cases43. In the present study, the optimal collimator setting is affected by the complex-shaped target of HIS-WBRT and thus different from the above findings. For the dual-arc VMAT technique adopted for HIS-WBRT, the optimal plan quality was acquired with $\Delta \theta = 90^\circ$, while the effect from the specific setting of each arc was relatively insignificant.

For the $\Delta \theta = 90^\circ$ plans with different collimator angle combinations, the gamma-index analysis results shown in Tables 4 and 5 indicated that the passing rates could be affected by the specific angle of each arc. Although the passing rate with the collimator closer to 0° showed preferable results in this study, it should be noted that the QA result could be associated with many factors, such as the dosimetric leaf gap, tongue-and-groove effect, interleaf leakage, and intra- and inter-leaf transmission settings of MLC32–44. For the PDP algorithm in the Eclipse TPS, these MLC configuration parameters are constant for all collimator and gantry angles, but in practice, they may vary for different situations. The leaf position accuracy could be affected by the gantry rotation with different collimator angles due to gravitational effects imposed on the leaf carriage system45. The varying MLC parameters could yield a significant dose error, especially for highly modulated plans. Therefore, with regard to the plan QA for other institutions, the preferable result may vary.

Conclusions
This study demonstrated the role of collimator settings in dual-arc VMAT planning for HIS-WBRT. The intersection angle between two collimator settings, $\Delta \theta$, showed a significant influence on the plan quality. With $\Delta \theta$ approaching 90°, a nearly continuous improvement was observed in the dose distributions and MUs. However, with the same $\Delta \theta = 90^\circ$, the effect from the specific collimator angle of each arc was relatively trivial. The QA results indicated that the 300°/30°, 315°/45°, and 330°/60° plans had a better delivery accuracy than the 280°/10° and 350°/80° plans.

Data availability
Research data analyzed in this study are included as supplementary materials. Other data that support the findings of this study are available from the corresponding author upon reasonable request.
References

1. Slotman, B. et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. *N. Engl. J. Med.* 357, 664–672 (2007).

2. Kotallah, J., Yu, E., Markman, B. R. & Evans, W. K. Practice guideline on prophylactic cranial irradiation in small-cell lung cancer. *Int. J. Radiat. Oncol. Biol. Phys.* 50, 309–316 (2001).

3. Andrews, D. W. et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one or three brain metastases: Phase III results of the RTOG 9508 randomised trial. *Lancet* 363, 1665–1672 (2004).

4. Welzel, G. et al. Memory function before and after whole brain radiotherapy in patients with and without brain metastases. *Int. J. Radiat. Oncol. Biol. Phys.* 72, 1311–1318 (2008).

5. Roman, D. D. & Speculudo, P. W. Neuropsychological effects of cranial radiation: Current knowledge and future directions. *Int. J. Radiat. Oncol. Biol. Phys.* 31, 983–998 (1995).

6. Kirby, N., Chuang, C., Pouliot, J., Hwang, A. & Barani, I. J. Physics strategies for sparing neural stem cells during whole-brain radiation treatments. *Med. Phys.* 38, 5338–5344 (2011).

7. Gondi, V., Herrmann, B. P., Mehta, M. P. & Tome, W. A. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. *Int. J. Radiat. Oncol. Biol. Phys.* 83, e487–e493 (2012).

8. Gondi, V. et al. Hippocampal-sparing whole-brain radiotherapy: A “how-to” technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy. *Int. J. Radiat. Oncol. Biol. Phys.* 78, 1244–1252 (2010).

9. Gondi, V. et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): A phase II multi-institutional trial. *J. Clin. Oncol.* 32, 3810–3816 (2014).

10. Rao, M. et al. Comparison of Elekta VMAT with helical tomotherapy and fixed field IMRT: Plan quality, delivery efficiency and accuracy. *Med. Phys.* 37, 1350–1359 (2010).

11. Wolff, D. et al. Volumetric modulated arc therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D-conformal RT for treatment of prostate cancer. *Radiother. Oncol.* 93, 226–233 (2009).

12. Otto, K. Volumetric modulated arc therapy: IMRT in a single gantry arc. *Med. Phys.* 35, 310–317 (2008).

13. Kim, H., Li, R., Lee, R. & Xing, L. Beam’s-eye-view dosimetrics (BEVD) guided rotational station parameter optimized radiation therapy (SPORT) planning based on reweighted total variation minimization. *Phys. Med. Biol.* 60, N71–82 (2015).

14. Otto, K. Letter to the editor on “single-arc IMRT?”. *Phys. Med. Biol.* 54, L37–L39 (2009).

15. Okumura, M., Obata, Y., Shimomura, K., Tamura, M. & Nishimura, Y. The effect of gantry and collimator angles on leaf limited velocity and position in dynamic multileaf collimator intensity-modulated radiation therapy. *Phys. Med. Biol.* 55, 3101–3110 (2010).

16. Sandrini, E. S., da Silva, A. X. & da Silva, C. M. Evaluation of collimator rotation for volumetric modulated arc therapy lung stereotactic body radiation therapy using flattening filter free. *Appl. Radiat. Isot.* 141, 257–260 (2018).

17. Li, M. H., Hwang, S. F., Chang, C. C., Lin, J. C. & Tsai, J. T. Variations in dosimetric distribution and plan complexity with collimator angles in hypofractionated volumetric arc radiotherapy for treating prostate cancer. *J. Appl. Clin. Med. Phys.* 19, 93–102 (2018).

18. Murtaza, G., Mehmoond, S., Favretto, M. S. & Cora, S. Optimal VMAT delivery for Elekta MLC beam modulator: A study of collimator rotation for head and neck planning. *J. Med. Imaging Radiat. Sci.* 51, 289–298 (2020).

19. Li, Q. I. et al. Collimator rotation in volumetric modulated arc therapy for craniospinal irradiation and the dose distribution in the beam isocenter region. *Radiat. Oncol.* 10, 235 (2015).

20. Tas, B., Bilge, H. & Ozturk, S. T. An investigation of the dose distribution effect related with collimator angle in volumetric arc therapy of prostate cancer. *J. Med. Phys.* 41, 100–105 (2016).

21. Du, W. L., Johnson, J. L., Jiang, W. & Kuchadker, R. J. On the selection of gantry and collimator angles for isocenter localization using Winston–Lutz tests. *J. Appl. Clin. Med. Phys.* 17, 167–178 (2016).

22. Ohira, S. et al. Effect of collimator angle on HyperArc stereotactic radiosurgery planning for single and multiple brain metastases. *Med. Dosim.* 45, 85–91 (2020).

23. Bai, S. et al. Effect of MLC leaf position, collimator rotation angle, and gantry rotation angle errors on intensity-modulated radiotherapy plans for nasopharyngeal carcinoma. *Med. Dosim.* 38, 143–147 (2013).

24. Lyu, Q. et al. VMAT optimization with dynamic collimator rotation. *Med. Phys.* 45, 2399–2410 (2018).

25. Lambrecht, M. et al. Radiation dose constraints for organs at risk in neuro-oncology; the European particle therapy network consensus. *Radiother. Oncol.* 128, 26–36 (2018).

26. ICRU. ICRU report 83: Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). *J. Int. Comm. Radiat. Units Meas.* 10, 1–106 (2010).

27. ICRU. ICRU report 91: Prescribing, recording, and reporting of stereotactic treatments with small photon beams. *J. Int. Comm. Radiat. Units Meas.* 14, 1–145 (2014).

28. Low, D. A., Harms, W. B., Mutic, S. & Purdy, J. A. A technique for the quantitative evaluation of dose distributions. *Med. Phys.* 25, 656–661 (1998).

29. Moon, S. Y., Yoon, M., Chung, M., Chung, W. K. & Kim, D. W. Comparison of the extent of hippocampal sparing according to the tilt of a patient’s head during WBRT using linear accelerator-based IMRT and VMAT. *Med. Phys.* 32, 657–663 (2016).

30. Jiang, A. et al. Dosimetric evaluation of four whole brain radiation therapy approaches with hippocampus and inner ear avoidance and simultaneous integrated boost for limited brain metastases. *Radiat. Oncol.* 14, 46 (2019).

31. Krayenbuehl, J., Di Martino, M., Guckenberger, M. & Andratschke, N. Improved plan quality with automated radiotherapy planning for whole brain with hippocampus sparing: A comparison to the RTOG 0933 trial. *Radiol. Oncol.* 12, 161 (2017).

32. Zhang, P. et al. Optimization of collimator trajectory in volumetric modulated arc therapy: Development and evaluation for paraspinal SBRT. *Int. J. Radiat. Oncol. Biol. Phys.* 77, 591–599 (2010).

33. Ahn, R. S. et al. Dosimetric effects of sectional adjustments of collimator angles on volumetric modulated arc therapy for irregularly-shaped targets. *PloS One* 12, e0174924 (2017).

34. Kim, J. I., Ahn, B. S., Choi, C. H., Park, J. M. & Park, S. Y. Optimal collimator rotation based on the outline of multiple brain targets in VMAT. *Radiat. Oncol.* 13, 88 (2018).

35. de Boer, J., Wolf, A. L., Szeto, Y. Z., van Herk, M. & Sonke, J. J. Dynamic collimator angle adjustments during volumetric modulated arc therapy to account for prostate rotations. *Int. J. Radiat. Oncol. Biol. Phys.* 91, 1096–1105 (2015).

36. Murtaza, G., Toftegaard, J., Khan, E. U. & Poulsen, P. R. Volumetric modulated arc therapy with dynamic collimator rotation for improved multileaf collimator tracking of the prostate. *Radiother. Oncol.* 122, 109–115 (2017).

37. Kokrants, R., van Amerongen, J. H. M. & Craft, D. Technical note: Improving VMAT delivery efficiency by optimizing the dynamic collimator trajectory. *Med. Phys.* 46, 3877–3882 (2019).

38. Hernandez, V. et al. What is plan quality in radiotherapy? The importance of evaluating dose metrics, complexity, and robustness of treatment plans. *Radiother. Oncol.* 153, 23–30 (2020).

39. Gotstled, J., Hauer, A. K. & Back, A. Development and evaluation of aperture-based complexity metrics using film and EPID measurements of static MLC openings. *Med. Phys.* 42, 3911–3921 (2015).
40. Masi, L., Doro, R., Favuzza, V., Cipressi, S. & Livi, L. Impact of plan parameters on the dosimetric accuracy of volumetric modulated arc therapy. Med. Phys. 40, 071718 (2013).
41. Mancosu, P. et al. Collimator angle influence on dose distribution optimization for vertebral metastases using volumetric modulated arc therapy. Med. Phys. 37, 4133–4137 (2010).
42. Bayouth, J. E. Siemens multileaf collimator characterization and quality assurance approaches for intensity-modulated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 71, 593–97 (2008).
43. Kumaraswamy, L. K., Schmitt, J. D., Bailey, D. W., Xu, Z. Z. & Podgorsak, M. B. Spatial variation of dosimetric leaf gap and its impact on dose delivery. Med. Phys. 41, 111711 (2014).
44. Gao, Z., Szanto, J. & Geric, L. Using multileaf collimator interleaf leakage to extract absolute spatial information from electronic portal imaging device images. J. Appl. Clin. Med. Phys. 8, 1–9 (2005).
45. Klein, E. E. et al. Task group 142 report: Quality assurance of medical accelerators. Med. Phys. 36, 4197–4212 (2009).

Acknowledgements
This work was supported by the National Natural Science Foundation of China [No. 81773353]; the Jilin Scientific and Technological Development Program [Nos. 20190201204C, 20200601005C]; and the Jilin Province Special Project of Medical and Health Talents [No. JLSCZD2019-032].

Author contributions
H.W. conceived and designed the study. W.S. and K.C. wrote the paper. Y.L., W.X. and C.G. are responsible for data acquisition and statistical analyses. X.Y. and L.W. prepared the figures. L.D. and Y.S. made critical revisions to the paper. All authors reviewed the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-98530-7.

Correspondence and requests for materials should be addressed to H.W.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021